Novartis India has launched Pluvicto, the country’s first regulator-approved radioligand therapy for PSMA-positive prostate cancer. The treatment offers a targeted approach for metastatic cases, addressing a growing cancer burden among Indian men, with nearly 250,000 new cases reported annually.